Indirect targeting of GCase activity includes pharmacological or genetic LRRK2 inhibition, assessed in GBA1- and LRRK2-PD iPSC-derived DAergic neurons (Nguyen and Krainc, 2018; Ysselstein et al., 2019). Here, GBA1 is linked to Parkinson disease.